TCGA-OL-A66P-01A-11R-A31O-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 14
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.550
- XENOBIOTIC_METABOLISM+0.410
- INTERFERON_GAMMA_RESPONSE+0.390
- INFLAMMATORY_RESPONSE+0.380
- CHOLESTEROL_HOMEOSTASIS+0.370
- IL2_STAT5_SIGNALING+0.360
- OXIDATIVE_PHOSPHORYLATION+0.360
- COAGULATION+0.340
- FATTY_ACID_METABOLISM+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
Top 10 suppressed
- MITOTIC_SPINDLE-0.480
- PROTEIN_SECRETION-0.480
- TGF_BETA_SIGNALING-0.440
- G2M_CHECKPOINT-0.420
- UV_RESPONSE_DN-0.370
- WNT_BETA_CATENIN_SIGNALING-0.360
- E2F_TARGETS-0.350
- NOTCH_SIGNALING-0.340
- ESTROGEN_RESPONSE_EARLY-0.220
- MYC_TARGETS_V1-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | da7cbc0a-95dc-4303-a5dd-75857c066f3b | — | — | 0.855 |
| 2 | TCGA-BH-A5J0-01A-11R-A27Q-07 | — | B | 0.847 |
| 3 | d3be84d5-9dd7-4366-9aea-532dc76f19ba | — | — | 0.841 |
| 4 | TCGA-BH-A0AW-01A-11R-A056-07 | — | C | 0.838 |
| 5 | SAMN03290925 | — | — | 0.836 |
| 6 | BS_6NTXGQAC | Ganglioglioma | — | 0.834 |
| 7 | MDT-AP-2183 | Med | Medulloblastoma | 0.831 |
| 8 | SJEPD001516_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.829 |
| 9 | ERR2598280 | fetal | fetal | 0.829 |
| 10 | TCGA-AC-A5XS-01A-11R-A29R-07 | — | B | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |